Medpace Holdings Inc. (MEDP) saw its stock price plummet 6.15% in after-hours trading on Monday, despite reporting first-quarter earnings that beat analyst expectations. The sharp decline comes as investors appear to be focusing on the company's full-year guidance, which fell short of market estimates.

For the first quarter of 2025, Medpace reported impressive results: - Revenue of $558.57 million, surpassing the IBES estimate of $527.2 million - Earnings per share (EPS) of $3.67, significantly higher than the IBES estimate of $3.06 - Net income of $114.595 million, up from $102.591 million in the same quarter last year

However, the company's outlook for the full year 2025 seems to have disappointed investors: - EPS guidance of $12.26 to $13.04 - Revenue forecast of $2.140 billion to $2.240 billion, representing growth of only 1.5% to 6.2% over 2024 revenue The modest growth projection, coupled with a decrease in net new business awards (down 18.8% to $500.0 million) and a lower book-to-bill ratio of 0.90x, likely contributed to the negative after-hours reaction. These factors suggest potential challenges in maintaining the company's growth trajectory, despite the strong quarterly performance.